Trial
NCT02333162
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
University of Chicago
Collaborators
National Cancer Institute (NCI)
Condition
Previously Treated Myelodysplastic Syndrome
Intervention
Fludarabine Phosphate
Why stopped
Enrollment on hold pending amendment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-30